Pico-Tesla expands Phase III pivotal clinical trial of Magneceutical® Therapy for Parkinson’s disease

Three Principal Investigators added, in Denver and Tampa

“We are making great progress toward establishing the clinical potential of Magneceutical® Therapy for Parkinson’s patients.”
Allen Braswell, CEO, Pico-Tesla

http://www.businesswire.com/news/hom...clinical-trial

LITTLETON, Colo.--(BUSINESS WIRE)--Pico-Tesla, The Magneceutical® Company, announced today that it has expanded its ongoing Phase III pivotal clinical trial by adding three Principal Investigators, including two university-affiliated clinicians: one in Denver; and one in Tampa. In addition, Pico-Tesla announced that enrollment is approaching 50% of the patients required for this pivotal clinical trial.

Pico-Tesla’s Magneceutical® Therapy involves the use of an extremely low-level electromagnetic field (EMF) applied by a specially designed device—the Resonator™, invented by Dr. Jerry I. Jacobson, along with proprietary therapeutic protocols—and is currently in clinical trials to determine its effectiveness for improving the signs and symptoms of several diseases, including Parkinson’s disease, atrial fibrillation, Alzheimer’s disease, fibromyalgia and osteoarthritis.